Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition
Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies. As such, inhibiting HER3 could have broad applicability to the treatment of EGFR- and HER2-drive...
Main Authors: | Takuya Osada, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, Hongtao Guo, Xiao-Yi Yang, Cong-Xiao Liu, Kensuke Kaneko, Gloria Broadwater, H. Kim Lyerly |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-06-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1315495 |
Similar Items
-
Targeting the ERβ/HER Oncogenic Network in <i>KRAS</i> Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
by: Abdulaziz A. Almotlak, et al.
Published: (2021-12-01) -
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
by: Regina Padmanabhan, et al.
Published: (2020-03-01) -
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
by: Regina Padmanabhan, et al.
Published: (2022-12-01) -
Research Progress of PD-1/PD-L1 Inhibitor Combined with Trastuzumab in HER2-positive Breast Cancer
by: CHANG Jinyi, et al.
Published: (2022-09-01) -
Immunological Landscape of HER-2 Positive Breast Cancer
by: Santiago Moragon, et al.
Published: (2022-06-01)